Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Bladder Cancer

Free Subscription Articles published in J Urol Retrieve available abstracts of 165 articles: HTML format Text format

Single Articles

February 2012
1. WOOD DP
   Re: International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial.
   J Urol. 2012;187:473.
   PubMed     Text format     Related articles   
   
   
   
   
2. WOOD DP
   Re: bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
   J Urol. 2012;187:473-4.
   PubMed     Text format     Related articles   
   
   
   
   January 2012
3. ZHANG X , Shi X, Li J, Hu Z, et al
   A Novel Therapeutic Vaccine of Mouse GM-CSF Surface Modified MB49 Cells Against Metastatic Bladder Cancer.
   J Urol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. FERNANDEZ MI , Lopez JF, Vivaldi B, Coz F, et al
   Long-Term Impact of Arsenic in Drinking Water on Bladder Cancer Health Care and Mortality Rates 20 Years After End of Exposure.
   J Urol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. KAMAT AM , Dickstein RJ, Messetti F, Anderson R, et al
   Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guerin Therapy for Bladder Cancer: Results of a Prospective Trial.
   J Urol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. WOOD DP
   Re: Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
   J Urol. 2012;187:352-3.
   PubMed     Text format     Related articles   
   
   
   
   December 2011
7. SALINAS-SANCHEZ AS , Donate-Moreno MJ, Lopez-Garrido MP, Gimenez-Bachs JM, et al
   Role of CYP1B1 Gene Polymorphisms in Bladder Cancer Susceptibility.
   J Urol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. ESWARA JR , Efstathiou JA, Heney NM, Paly J, et al
   Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder Cancer.
   J Urol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. HERR HW
   Intravesical Bacillus Calmette-Guerin Outcomes in Patients With Bladder Cancer and Asymptomatic Bacteriuria.
   J Urol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. REIS LO , Ferreira U, Billis A, Cagnon VH, et al
    Anti-Angiogenic Effects of the Superantigen Staphylococcal Enterotoxin B and Bacillus Calmette-Guerin Immunotherapy for Nonmuscle Invasive Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. MEIJER RP , Nunnink CJ, Wassenaar AE, Bex A, et al
    Standard Lymph Node Dissection for Bladder Cancer: Significant Variability in the Number of Reported Lymph Nodes.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. SHARIAT SF , Chromecki TF, Cha EK, Karakiewicz PI, et al
    Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. KILTIE AE
    Using Gene Polymorphisms to Assess Bladder Cancer Risk: Progress and Challenges.
    J Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
14. DEB AA , Wilson SS, Rove KO, Kumar B, et al
    Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
    J Urol. 2011;186:2426-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. PELLUCCHI F , Freschi M, Ibrahim B, Rocchini L, et al
    Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors.
    J Urol. 2011;186:2194-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. MONTIRONI R
    Editorial comment.
    J Urol. 2011;186:2199-200.
    PubMed     Text format     Related articles   
    
    
    
    November 2011
17. VAN RHIJN BW , Kwast TH, Liu L, Fleshner NE, et al
    The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. TODENHOEFER T , Hennenlotter J, Witstruk M, Gakis G, et al
    Influence of Renal Excretory Function on the Performance of Urine Based Markers to Detect Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. WOOD DP
    Re: long-term follow-up of t1 high-grade bladder cancer after intravesical bacille calmette-guerin treatment.
    J Urol. 2011;186:1809-10.
    PubMed     Text format     Related articles   
    
    
    
    
20. WOOD DP
    Re: Long-Term Outcomes of a Randomized Controlled Trial Comparing Thermochemotherapy With Mitomycin-C Alone as Adjuvant Treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC).
    J Urol. 2011;186:1808-9.
    PubMed     Text format     Related articles   
    
    
    
    October 2011
21. BRAUSI M , Witjes JA, Lamm D, Persad R, et al
    A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. HUSMANN D
    Editorial comment.
    J Urol. 2011;186.
    PubMed     Text format     Related articles   
    
    
    
    
23. FRANKE EI , Misseri R, Cain MP, Kaefer M, et al
    Nephrogenic adenoma in the augmented bladder.
    J Urol. 2011;186.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. KOKOROWSKI PJ , Routh JC, Borer JG, Estrada CR, et al
    Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis.
    J Urol. 2011;186:1437-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. SERRETTA V
    Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
    J Urol. 2011;186:1557.
    PubMed     Text format     Related articles   
    
    
    
    September 2011
26. WOSNITZER MS , Domingo-Domenech J, Castillo-Martin M, Ritch C, et al
    Predictive Value of Microtubule Associated Proteins Tau and Stathmin in Patients With Nonmuscle Invasive Bladder Cancer Receiving Adjuvant Intravesical Taxane Therapy.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. JEON HG , Yoon CY, Yu JH, Park MJ, et al
    Induction of Caspase Mediated Apoptosis and Down-Regulation of Nuclear Factor-kappaB and Akt Signaling are Involved in the Synergistic Antitumor Effect of Gemcitabine and the Histone Deacetylase Inhibitor Trichostatin A in Human Bladder Cancer Cells.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. KAMAT AM
    Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Con.
    J Urol. 2011;186:788-9.
    PubMed     Text format     Related articles   
    
    
    
    
29. ROSEVEAR HM , Lightfoot AJ, Birusingh KK, Maymi JL, et al
    Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ.
    J Urol. 2011;186:817-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. HERR HW
    Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Pro.
    J Urol. 2011;186:787-8.
    PubMed     Text format     Related articles   
    
    
    
    August 2011
31. NEUTSCH L , Plattner VE, Polster-Wildhofen S, Zidar A, et al
    Lectin Mediated Biorecognition as a Novel Strategy for Targeted Delivery to Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. ZEHNDER P , Studer UE, Skinner EC, Dorin RP, et al
    Super Extended Versus Extended Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Comparative Study.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. MIOCINOVIC R , Gong MC, Ghoneim IA, Fergany AF, et al
    Presacral and Retroperitoneal Lymph Node Involvement in Urothelial Bladder Cancer: Results of a Prospective Mapping Study.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. SELMAN SH , Keck RW
    A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model.
    J Urol. 2011;186:702-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. GOLAN S , Sopov V, Baniel J, Groshar D, et al
    Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study.
    J Urol. 2011;186:436-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. RODRIGUEZ FABA O , Palou J, Rosales A, Breda A, et al
    Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy.
    J Urol. 2011;186:442-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
37. ABDOLLAH F , Schmitges J, Sun M, Thuret R, et al
    Hospital and Surgical Caseload are Predictors of Comprehensive Surgical Treatment for Bladder Cancer: A Population Based Study.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. MORGAN TM , Keegan KA, Barocas DA, Ruhotina N, et al
    Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. BHALANI SM , Casalino DD, Manvar AM
    Paraganglioma of the bladder.
    J Urol. 2011;186:279-80.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
40. PILCHOWSKI R , Stohr R, von Eggeling F, Hartmann A, et al
    Specific Protein Patterns Characterize Metastatic Potential of Advanced Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. ZUIVERLOON TC , Tjin SS, Busstra M, Bangma CH, et al
    Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. MCKIERNAN JM , Barlow LJ, Laudano MA, Mann MJ, et al
    A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guerin Refractory Nonmuscle Invasive Bladder Cancer.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. KIM WJ , Lee JW, Quan C, Youn HJ, et al
    Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300.
    J Urol. 2011;185:2366-75.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. HAUTMANN RE , de Petriconi RC, Volkmer BG
    25 years of experience with 1,000 neobladders: long-term complications.
    J Urol. 2011;185:2207-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. DALBAGNI G , Bochner BH, Cronin A, Herr HW, et al
    A plea for a uniform surveillance schedule after radical cystectomy.
    J Urol. 2011;185:2091-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. JEONG IG , You D, Kim JW, Song C, et al
    Outcomes of single lymph node positive urothelial carcinoma after radical cystectomy.
    J Urol. 2011;185:2085-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
47. YAMAMOTO H , Sutoh M, Hatakeyama S, Hashimoto Y, et al
    Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells.
    J Urol. 2011;185:1930-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. AYARI C , Bergeron A, LaRue H, Menard C, et al
    Toll-like receptors in normal and malignant human bladders.
    J Urol. 2011;185:1915-21.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. MALLIN K , David KA, Carroll PR, Milowsky MI, et al
    Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007).
    J Urol. 2011;185:1631-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. CROCKETT DG , Wagner DG, Holmang S, Johansson SL, et al
    Upper urinary tract carcinoma in Lynch syndrome cases.
    J Urol. 2011;185:1627-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. STROPE SA
    Editorial comment.
    J Urol. 2011;185:1626.
    PubMed     Text format     Related articles   
    
    
    
    
52. ITO Y , Kikuchi E, Tanaka N, Miyajima A, et al
    Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma.
    J Urol. 2011;185:1621-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. WOOD DP
    Re: Two Instillations of Epirubicin as Prophylaxis for Recurrence After Transurethral Resection of Ta and T1 Transitional Cell Bladder Cancer: A Prospective, Randomized Controlled Study.
    J Urol. 2011;185:1644.
    PubMed     Text format     Related articles   
    
    
    
    
54. WOOD DP
    Re: Practice Patterns and Recurrence After Partial Cystectomy for Bladder Cancer.
    J Urol. 2011;185:1643.
    PubMed     Text format     Related articles   
    
    
    
    
55. WOOD DP
    Re: Mechanisms of Recurrence of Ta/T1 Bladder Cancer.
    J Urol. 2011;185:1642.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
56. CHAN ES , Patel AR, Larchian WA, Heston WD, et al
    In Vivo Targeted Contrast Enhanced Micro-Ultrasound to Measure Intratumor Perfusion and Vascular Endothelial Growth Factor Receptor 2 Expression in a Mouse Orthotopic Bladder Cancer Model.
    J Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
57. ABDOLLAH F , Sun M, Shariat SF, Schmitges J, et al
    The Importance of Pelvic Lymph Node Dissection in the Elderly Population: Implications for Interpreting the 2010 National Comprehensive Cancer Network Practice Guidelines for Bladder Cancer Treatment.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. WILLIAMSON SR , Cheng L
    Perivascular epithelioid cell tumor of the bladder.
    J Urol. 2011;185:1473-4.
    PubMed     Text format     Related articles   
    
    
    
    
59. HOTALING JM , Wright JL, Pocobelli G, Bhatti P, et al
    Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study.
    J Urol. 2011;185:1210-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
60. KHADJAVI A , Barbero G, Destefanis P, Mandili G, et al
    Evidence of Abnormal Tyrosine Phosphorylated Proteins in the Urine of Patients With Bladder Cancer: The Road Toward a New Diagnostic Tool?
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. SIROY AE , MacLennan GT
    Primary melanoma of the bladder.
    J Urol. 2011;185:1096-7.
    PubMed     Text format     Related articles   
    
    
    
    
62. YOUSSEF RF , Shariat SF, Kapur P, Kabbani W, et al
    Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder.
    J Urol. 2011;185:1112-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. MAEDA T , Kikuchi E, Matsumoto K, Miyajima A, et al
    Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    J Urol. 2011;185:802-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
64. SONPAVDE G , Khan MM, Svatek RS, Lee R, et al
    Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. NEULANDER EZ , Katz T, Yusim I, Kaneti J, et al
    Re: Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder Cancer C. J. Stimson, M. S. Cookson, D. A. Barocas, P. E. Clark, J. E. Humphrey, S. G. Patel, J. A. Smith, Jr. and S. S. Chan
    J Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
66. LU Z , Yeh TK, Wang J, Chen L, et al
    Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. SHIMKO MS , Tollefson MK, Umbreit EC, Farmer SA, et al
    Long-term complications of conduit urinary diversion.
    J Urol. 2011;185:562-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. BASSI PF , Volpe A, D'Agostino D, Palermo G, et al
    Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study.
    J Urol. 2011;185:445-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. WOOD DP
    Re: Pathological Stage Review is Indicated in Primary pT1 Bladder Cancer.
    J Urol. 2011;185:468.
    PubMed     Text format     Related articles   
    
    
    
    
70. WOOD DP
    Re: Gene Signatures for the Prediction of Response to Bacillus Calmette-Guerin Immunotherapy in Primary pT1 Bladder Cancers.
    J Urol. 2011;185:468-469.
    PubMed     Text format     Related articles   
    
    
    
    
71. GRIEBLING TL
    Re: Impact of Patient Age on Outcome Following Bladder-Preserving Treatment for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2011;185:466-467.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
72. YOON CY , Park MJ, Lee JS, Lee SC, et al
    The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line.
    J Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. PRUTHI RS , Smith AM
    Editorial comment.
    J Urol. 2011;185:96.
    PubMed     Text format     Related articles   
    
    
    
    
74. GHAVAMIAN R
    Editorial comment.
    J Urol. 2011;185:84.
    PubMed     Text format     Related articles   
    
    
    
    
75. DAVIS JW , Gaston K, Anderson R, Dinney CP, et al
    Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection.
    J Urol. 2011;185:79-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. AGHAZADEH MA , Barocas DA, Salem S, Clark PE, et al
    Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort.
    J Urol. 2011;185:85-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. MONTIE JE
    Re: effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer.
    J Urol. 2011;185:103.
    PubMed     Text format     Related articles   
    
    
    
    
78. MONTIE JE
    Re: gemcitabine versus bacille calmette-guerin after initial bacille calmette-guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
    J Urol. 2011;185:101-2.
    PubMed     Text format     Related articles   
    
    
    
    December 2010
79. YIM MS , Ha YS, Kim IY, Yun SJ, et al
    HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. BLACK PC , Brown GA, Dinney CP, Kassouf W, et al
    Receptor Heterodimerization: A New Mechanism for Platelet-Derived Growth Factor Induced Resistance to Anti-Epidermal Growth Factor Receptor Therapy for Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. SONPAVDE G , Khan MM, Lerner SP, Svatek RS, et al
    Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. TANAKA N , Kikuchi E, Matsumoto K, Miyajima A, et al
    Frequency of Tumor Recurrence: A Strong Predictor of Stage Progression in Initially Diagnosed Nonmuscle Invasive Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. PAVLIDAKEY PG , MacLennan GT, Goldman HB
    Nephrogenic adenoma of the bladder.
    J Urol. 2010;184:2535-6.
    PubMed     Text format     Related articles   
    
    
    
    
84. HIGUCHI TT , Granberg CF, Fox JA, Husmann DA, et al
    Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy.
    J Urol. 2010;184:2492-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. CAIN MP
    Editorial comment.
    J Urol. 2010;184:2496-7.
    PubMed     Text format     Related articles   
    
    
    
    
86. GRADY R
    Editorial comment.
    J Urol. 2010;184:2497.
    PubMed     Text format     Related articles   
    
    
    
    
87. KRUPSKI TL
    Malignancy and augmentation--how worried should we be?
    J Urol. 2010;184:2231-2.
    PubMed     Text format     Related articles   
    
    
    
    November 2010
88. GREGG JR , Cookson MS, Phillips S, Salem S, et al
    Effect of Preoperative Nutritional Deficiency on Mortality After Radical Cystectomy for Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. ROSEVEAR HM , Lightfoot AJ, Nepple KG, O'Donnell MA, et al
    Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guerin Plus Interferon-alpha
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. FEDELI U , Fedewa SA, Ward EM
    Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
91. MOURACADE P
    Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou and C. H. Huang J Urol 2010; 183: 56-61.
    J Urol. 2010;184:1571.
    PubMed     Text format     Related articles   
    
    
    
    
92. WILLIS D , Canales BK, Cheng L, MacLennan GT, et al
    Neural neoplasms of the bladder.
    J Urol. 2010;184:1492-3.
    PubMed     Text format     Related articles   
    
    
    
    
93. STIMSON CJ , Chang SS, Barocas DA, Humphrey JE, et al
    Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series.
    J Urol. 2010;184:1296-300.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. REN H , Yuan Z, Waltzer W, Shroyer K, et al
    Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography.
    J Urol. 2010;184:1499-506.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
95. RYK C , Steineck G, Wiklund NP, Nyberg T, et al
    The (CCTTT)n Microsatellite Polymorphism in the Nitric Oxide Synthase 2 Gene May Influence Bladder Cancer Pathogenesis.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. STENZL A , Burger M, Fradet Y, Mynderse LA, et al
    Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. NEPPLE KG , Lightfoot AJ, Rosevear HM, O'Donnell MA, et al
    Bacillus Calmette-Guerin With or Without Interferon alpha-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. BJURLIN MA , Goble SM, Hollowell CM
    Smoking Cessation Assistance for Patients With Bladder Cancer: A National Survey of American Urologists.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. ROSEVEAR HM , Lightfoot AJ, Nepple KG, O'Donnell MA, et al
    Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Plus Interferon alpha-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic Devices.
    J Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. HUANG YH
     Re: Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. M. K. Tollefson, M. L. Blute, S. A. Farmer and I. Frank J Urol 2010; 183: 81-86.
     J Urol. 2010;184:1222-3.
     PubMed     Text format     Related articles   
     
     
     
     
101. YING-YUE J , Shen SH, Wang JH
     Unusual presentation of urothelial carcinoma of the bladder with noncontiguous rectal and diffuse muscular skeletal metastases.
     J Urol. 2010;184:1163-4.
     PubMed     Text format     Related articles   
     
     
     
     
102. TILKI D , Svatek RS, Novara G, Seitz M, et al
     Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
     J Urol. 2010;184:888-94.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. ISHIKAWA S , Abe T, Shinohara N, Harabayashi T, et al
     Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract.
     J Urol. 2010;184:883-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. JOHANNES JR , Nelson E, Bibbo M, Bagley DH, et al
     Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
     J Urol. 2010;184:879-82.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. HAUTMANN RE , de Petriconi RC, Volkmer BG
     Lessons learned from 1,000 neobladders: the 90-day complication rate.
     J Urol. 2010;184:990-4.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     August 2010
106. ALVAREZ-MUGICA M , Cebrian V, Fernandez-Gomez JM, Fresno F, et al
     Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. SOLSONA E , Iborra I, Collado A, Rubio-Briones J, et al
     Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder Cancer.
     J Urol. 2010;184:475-481.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
108. BRYAN RT , Tselepis C
     Cadherin Switching and Bladder Cancer.
     J Urol. 2010;184:423-431.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
109. MCACHRAN SE , Williams DH, MacLennan GT
     Renal cell carcinoma metastasis to the bladder.
     J Urol. 2010;184:726-7.
     PubMed     Text format     Related articles   
     
     
     
     
110. SAGALOWSKY AI
     Editorial comment.
     J Urol. 2010;184:480-1.
     PubMed     Text format     Related articles   
     
     
     
     
111. TILKI D , Svatek RS, Karakiewicz PI, Novara G, et al
     pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder.
     J Urol. 2010;184:470-4.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
112. KASSOUF W
     Editorial comment.
     J Urol. 2010;184:469.
     PubMed     Text format     Related articles   
     
     
     
     
113. CHADE DC , Shariat SF, Adamy A, Bochner BH, et al
     Clinical outcome of primary versus secondary bladder carcinoma in situ.
     J Urol. 2010;184:464-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
114. OWEN HC , Giedl J, Wild PJ, Fine SW, et al
     Low frequency of epigenetic events in urothelial tumors in young patients.
     J Urol. 2010;184:459-63.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     July 2010
115. DING S , Nishizawa K, Kobayashi T, Oishi S, et al
     A Potent Chemotherapeutic Strategy for Bladder Cancer: (S)-Methoxy-Trityl-L-Cystein, a Novel Eg5 Inhibitor.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
116. CHADE DC , Shariat SF, Godoy G, Savage CJ, et al
     Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.
     J Urol. 2010;184:74-80.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
117. LERNER SP
     Editorial comment.
     J Urol. 2010;184:79-80.
     PubMed     Text format     Related articles   
     
     
     
     
118. MECHLIN CW , Tanner MJ, Chen M, Buttyan R, et al
     Gli2 expression and human bladder transitional carcinoma cell invasiveness.
     J Urol. 2010;184:344-51.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
119. GINSBERG DA
     Indications and complications of cystectomy in patients with neurogenic bladder.
     J Urol. 2010;184:10-1.
     PubMed     Text format     Related articles   
     
     
     
     
120. CHENG JN , Lawrentschuk N, Gyomber D, Rogerson J, et al
     Cystectomy in patients with spinal cord injury: indications and long-term outcomes.
     J Urol. 2010;184:92-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
121. HELLENTHAL NJ , Hussain A, Andrews PE, Carpentier P, et al
     Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
     J Urol. 2010;184:87-91.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
122. BENSON MC
     Editorial comment.
     J Urol. 2010;184:91.
     PubMed     Text format     Related articles   
     
     
     
     
123. BRIEN JC , Shariat SF, Herman MP, Ng CK, et al
     Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma.
     J Urol. 2010;184:69-73.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     June 2010
124. NOVARA G , Svatek RS, Karakiewicz PI, Skinner E, et al
     Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
     J Urol. 2010;183:2165-70.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
125. BENSON MC
     Editorial comment.
     J Urol. 2010;183:2170.
     PubMed     Text format     Related articles   
     
     
     
     
126. WANG LJ , Wong YC, Ng KF, Chuang CK, et al
     Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography.
     J Urol. 2010;183:2154-60.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
127. DONAT SM , Siegrist T, Cronin A, Savage C, et al
     Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
     J Urol. 2010;183:2171-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
128. DECASTRO GJ , Steinberg GD
     Editorial comment.
     J Urol. 2010;183:2176-7.
     PubMed     Text format     Related articles   
     
     
     
     May 2010
129. YANG J , Xu Z, Li J, Zhang R, et al
     XPC Epigenetic Silence Coupled With p53 Alteration Has a Significant Impact on Bladder Cancer Outcome.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
130. ALKHATEEB SS , Van Rhijn BW, Finelli A, van der Kwast T, et al
     Nonprimary pT1 Nonmuscle Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin is Associated With Higher Risk of Progression Compared to Primary T1 Tumors.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
131. LOTAN Y
     Editorial comment.
     J Urol. 2010;183:1685.
     PubMed     Text format     Related articles   
     
     
     
     
132. TILKI D , Reich O, Svatek RS, Karakiewicz PI, et al
     Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
     J Urol. 2010;183:1757-63.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
133. PENSON DF
     Editorial comment.
     J Urol. 2010;183:1769-70.
     PubMed     Text format     Related articles   
     
     
     
     
134. NGO TC , Gonzalgo ML
     Editorial comment.
     J Urol. 2010;183:1750.
     PubMed     Text format     Related articles   
     
     
     
     April 2010
135. GOULD JJ , Kenney PA, Rieger-Christ KM, Neto BS, et al
     Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
136. KLATTE T , Seligson DB, Rao JY, Yu H, et al
     Absent CD44v6 Expression is an Independent Predictor of Poor Urothelial Bladder Cancer Outcome.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
137. ADAM RM
     Histone Deacetylase Inhibitors and Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
138. GUEVARA A , Salomon L, Allory Y, Ploussard G, et al
     The Role of Tumor-Free Status in Repeat Resection Before Intravesical Bacillus Calmette-Guerin for High Grade Ta, T1 and CIS Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
139. ONG CH , Schmitt M, Thalmann GN, Studer UE, et al
     Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results.
     J Urol. 2010;183:1337-41.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
140. SAGALOWSKY AI
     Editorial comment.
     J Urol. 2010;183:1341-2.
     PubMed     Text format     Related articles   
     
     
     
     March 2010
141. AZUMI M , Kobayashi H, Aoki N, Sato K, et al
     Six-Transmembrane Epithelial Antigen of the Prostate as an Immunotherapeutic Target for Renal Cell and Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
142. DECASTRO GJ , Steinberg GD
     Are We Making Significant Progress in the Diagnosis and Management of Bladder Cancer?
     J Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
143. CAI T , Nesi G, Dal Canto M, Tinacci G, et al
     Loss of Heterozygosis on IFN-alpha Locus is a Prognostic Indicator of Bacillus Calmette-Guerin Response for Nonmuscle Invasive Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
144. GILBERT SM , Dunn RL, Hollenbeck BK, Montie JE, et al
     Development and Validation of the Bladder Cancer Index: A Comprehensive, Disease Specific Measure of Health Related Quality of Life in Patients With Localized Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
145. STIMSON CJ , Cookson MS, Barocas DA, Clark PE, et al
     Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
146. GOFRIT ON , Zorn KC, Shikanov S, Steinberg GD, et al
     Marker Lesion Experiments in Bladder Cancer-What Have We Learned?
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
147. SHARIAT SF , Youssef RF, Gupta A, Chade DC, et al
     Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
148. YEE DS , Shariat SF, Lowrance WT, Sterbis JR, et al
     Impact of Previous Radiotherapy for Prostate Cancer on Clinical Outcomes of Patients With Bladder Cancer.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
149. NEULANDER EZ , Katz T, Klein J, Kaneti J, et al
     Re: Transurethral partial cystectomy with continuous wave laser for bladder carcinoma. Y. Yang, Z.-t. Wei, X. Zhang, B.-F. Hong and G. Guo. J Urol 2009; 182: 66-69.
     J Urol. 2010;183:1257.
     PubMed     Text format     Related articles   
     
     
     
     
150. LANG EK , Rudman E, Hanano A, Jaworsky J, et al
     Computerized tomography reveals variable aggressiveness of transitional cell carcinoma of the bladder and bladder diverticulum.
     J Urol. 2010;183:1190.
     PubMed     Text format     Related articles   
     
     
     
     
151. MURPHY WM
     Editorial comment.
     J Urol. 2010;183:927.
     PubMed     Text format     Related articles   
     
     
     
     
152. LEE MC , Levin HS, Jones JS
     The role of pathology review of transurethral bladder tumor resection specimens in the modern era.
     J Urol. 2010;183:921-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
153. SAGALOWSKY AI
     Editorial comment.
     J Urol. 2010;183:928.
     PubMed     Text format     Related articles   
     
     
     
     
154. MURPHY DG
     Editorial comment.
     J Urol. 2010;183:869-70.
     PubMed     Text format     Related articles   
     
     
     
     
155. WEIZER AZ
     Editorial comment.
     J Urol. 2010;183:920.
     PubMed     Text format     Related articles   
     
     
     
     
156. KARAM JA , Wood CG
     Editorial comment.
     J Urol. 2010;183:870.
     PubMed     Text format     Related articles   
     
     
     
     
157. SVATEK RS , Fisher MB, Matin SF, Kamat AM, et al
     Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.
     J Urol. 2010;183:929-34.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
158. DONAT SM
     Editorial comment.
     J Urol. 2010;183:934.
     PubMed     Text format     Related articles   
     
     
     
     February 2010
159. MOSSBERG AK , Hou Y, Svensson M, Holmqvist B, et al
     HAMLET Treatment Delays Bladder Cancer Development.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
160. LUBET RA , Steele VE, Juliana MM, Grubbs CJ, et al
     Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
161. LERNER SP
     Editorial comment.
     J Urol. 2010;183:504.
     PubMed     Text format     Related articles   
     
     
     
     
162. WOOD DP
     Editorial comment.
     J Urol. 2010;183:515.
     PubMed     Text format     Related articles   
     
     
     
     
163. MAKAROV DV
     Editorial comment.
     J Urol. 2010;183:509.
     PubMed     Text format     Related articles   
     
     
     
     January 2010
164. CHADE DC , Laudone VP, Bochner BH, Parra RO, et al
     Oncological Outcomes After Radical Cystectomy for Bladder Cancer: Open Versus Minimally Invasive Approaches.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
165. PLOEG M , Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, et al
     Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry.
     J Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: